Buy Besponsa (inotuzumab) online
Besponsa (inotuzumab ozogamicin) is is a medication used for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
How to buy Besponsa (inotuzumab ozogamicin): You can order Besponsa from TheSocialMedwork if the drug has not been approved or is not available in your country.
Product Price is per Pill, Minimum Order is 50 Pills
Buy Besponsa (inotuzumab)
What is Besponsa (inotuzumab ozogamicin) for?
Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC) used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)1,2.
How does Besponsa (inotuzumab ozogamicin) work?
The active substance in Besponsa, inotuzumab ozogamicin, is a monoclonal antibody (a type of protein) that has been linked to a small molecule – N-acetyl-gamma-calicheamicin dimethylhydrazide – a cytotoxic agent that once activated provokes the death of cancer cells. The monoclonal antibody has been designed to recognise and attach to CD22 on the cancerous B cells. Once attached, the medicine is taken up by the cell where the cytotoxic agent becomes active, causing breaks in the cell’s DNA and thereby killing the cancer cell3.
Where has Besponsa (inotuzumab ozogamicin) been approved?
Besponsa (inotuzumab ozogamicin) was approved as a monotherapy for relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL)1,2 by:
- European Medical Agency (EMA), European Union, June 29, 20173
- Food and Drug Administration (FDA), USA, August 17, 20174
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.
Prior to all infusions, patients need to be pre-medicated with a corticosteroid, antipyretic, and antihistamine1,2.
Besponsa (inotuzumab ozogamicin) is given as an infusion into a vein lasting for at least one hour. The infusions are given on days 1, 8 and 15 of a 3 or 4-week treatment cycle. The treatment may be interrupted or the dose may be reduced if the patient develops certain serious side effects3.
Patients in whom Besponsa (inotuzumab ozogamicin) works well should receive 2 or 3 cycles, after which they can have a stem cell transplant to replace their bone marrow, the only curative treatment. Patients whose treatment works well, but who are not going to receive a stem cell transplant, may receive up to a maximum of 6 cycles of treatment. In patients who do not respond to treatment, Besponsa (inotuzumab ozogamicin) should be stopped after 3 cycles3.
Complete information about Besponsa (inotuzumab ozogamicin) dosage and administration can be found in the resources section1,2.
Use in specific populations
Besponsa (inotuzumab ozogamicin) can be fatal for a fetus, it is advised to avoid pregnancies and breast feeding1,2.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1,2.
Buy Besponsa (inotuzumab)